Clinical trials: Cancer, Advanced Solid Tumors
Hepatocellular Carcinoma, Liver Metastases
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
This is a phase 1b/2, multicenter, open-label, basket trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors alone and in combination with systemic intravenous (IV) administration of…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
- Trial name
- MASTERKEY-318 (NCT02509507)
- Testing
- Talimogene Laherparepvec, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 127 people
- Sponsor
- Amgen
Advanced Solid Tumor
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval as well as through a…
- Trial name
- NCT01106248
- Testing
- Eribulin Mesylate
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- Eisai Limited
Advanced Solid Tumors
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
This is a first-in-human, Phase I, multicenter, open label, dose escalation study to evaluate the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered IV in patients with any histologically…
- Trial name
- NCT03348514
- Testing
- CPX-POM - 30 mg/m^2, CPX-POM - 60 mg/m^2, CPX-POM - 120 mg/m^2
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- CicloMed LLC
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer, Malignant Solid Tumor
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by participants with solid tumor cancer. Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC) treated with…
- Trial name
- NCT00452413
- Testing
- enzastaurin, erlotinib
- Where
- 10 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Cancer, Advanced Solid Malignancies
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies.
- Trial name
- NCT01813474
- Testing
- olaparib
- Where
- 3 sites in Japan
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Malignancy, Metastasis
Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
Participants in this single-center, open-label, dose-escalation, Phase 1 study will initially receive intravenous (IV) olaratumab once every 2 weeks or on Days 1 and 8 every 3 weeks for 6 weeks (one cycle).
- Trial name
- NCT01199822
- Testing
- Olaratumab
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Breast Cancer
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response.
- Trial name
- VA (NCT00748553)
- Testing
- Azacitidine (Vidaza), Nab-paclitaxel (Abraxane)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy [SMMART])-adaptive clinical treatment [ACT]) works in treating patients with sarcoma…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma
- Trial name
- NCT06630325
- Testing
- Abemaciclib, Biopsy, Bone Scan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Advanced Solid Tumors, Neoplasms
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer
- Trial name
- NCT00879684
- Testing
- CVX-060
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
This phase I/II trial is studying the side effects and best dose of obatoclax mesylate when given together with topotecan hydrochloride and to see how well they work in treating patients with relapsed or refractory small cell…
- Trial name
- NCT00521144
- Testing
- obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms by Site
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or…
- Trial name
- NCT01968109
- Testing
- Relatlimab, Nivolumab, BMS-986213
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 1,482 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors.
- Trial name
- NCT02597036
- Testing
- LY3127804, Ramucirumab, Paclitaxel
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor, IDH1 Mutation
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
In this study, response to treatment and (progression free and overall) survival will be described and safety events of ivosidenib in combination with nivolumab will be summarized in patients with advanced solid tumors…
- Conditions
- Advanced Solid Tumor, IDH1 Mutation, Glioma
- Trial name
- NCT04056910
- Testing
- ivosidenib and nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jason J. Luke, MD
Solid Tumor
Safety Study of PLX108-01 in Patients With Solid Tumors
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable…
- Trial name
- NCT01004861
- Testing
- PLX3397
- Where
- 13 sites in United States
- Volunteers
- 132 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumors, Gastric Cancer
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT02318329
- Testing
- FPA144
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Five Prime Therapeutics, Inc.